Regeneron Historical Income Statement

REGN Stock

USD 778.50 9.50 1.21%

Historical analysis of Regeneron Pharmaceuticals income statement accounts such as Other Operating Expenses of 8.4 B, Operating Income of 4.2 B, EBIT of 4.2 B or Ebitda of 4.2 B can show how well Regeneron Pharmaceuticals performed in making a profits. Evaluating Regeneron Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Regeneron Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regeneron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regeneron Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

About Regeneron Income Statement Analysis

Regeneron Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Regeneron Pharmaceuticals shareholders. The income statement also shows Regeneron investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Regeneron Pharmaceuticals Income Statement Chart

At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 11th of December 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M.

Total Revenue Other Operating Expenses Cost Of Revenue Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Regeneron Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Regeneron Pharmaceuticals. It is also known as Regeneron Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Regeneron Pharmaceuticals income statement and represents the costs associated with goods and services Regeneron Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Regeneron Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 11th of December 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Net Income	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Research Development	Selling General Administrative	Extraordinary Items	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Non Recurring
Depreciation And Amortization		0.8	0.94	0.95	0.97	0.77	0.77	0.76	0.72	0.97	0.8	0.77	0.69	0.28	0.97	0.96	0.73	0.71	0.76	-0.01	0.85	0.73	0.91	-0.69
Interest Expense	0.8		0.73	0.74	0.72	0.64	0.64	0.63	0.6	0.69	0.69	0.64	0.59	0.09	0.72	0.66	0.49	0.61	0.64	0.08	0.72	0.63	0.78	-0.61
Total Revenue	0.94	0.73		1.0	0.97	0.93	0.93	0.93	0.89	0.92	0.94	0.94	0.81	0.52	0.92	0.93	0.72	0.88	0.86	0.19	0.66	0.51	0.85	-0.51
Gross Profit	0.95	0.74	1.0		0.98	0.91	0.91	0.91	0.86	0.94	0.92	0.91	0.79	0.49	0.94	0.95	0.72	0.86	0.84	0.16	0.7	0.56	0.85	-0.55
Other Operating Expenses	0.97	0.72	0.97	0.98		0.83	0.83	0.83	0.79	0.98	0.84	0.83	0.73	0.43	0.98	0.98	0.71	0.77	0.79	0.02	0.74	0.6	0.85	-0.58
Operating Income	0.77	0.64	0.93	0.91	0.83		1.0	1.0	0.97	0.72	0.99	1.0	0.86	0.65	0.72	0.74	0.65	0.97	0.89	0.41	0.41	0.25	0.73	-0.28
Ebit	0.77	0.64	0.93	0.91	0.83	1.0		1.0	0.98	0.72	0.99	1.0	0.86	0.65	0.72	0.74	0.66	0.98	0.89	0.4	0.41	0.24	0.73	-0.27
Ebitda	0.76	0.63	0.93	0.91	0.83	1.0	1.0		0.98	0.72	0.99	1.0	0.86	0.66	0.71	0.74	0.66	0.98	0.89	0.4	0.39	0.22	0.73	-0.24
Cost Of Revenue	0.72	0.6	0.89	0.86	0.79	0.97	0.98	0.98		0.66	0.96	0.98	0.89	0.65	0.67	0.68	0.65	0.97	0.91	0.4	0.32	0.14	0.72	-0.15
Total Operating Expenses	0.97	0.69	0.92	0.94	0.98	0.72	0.72	0.72	0.66		0.74	0.72	0.63	0.33	1.0	1.0	0.67	0.65	0.69	-0.09	0.81	0.68	0.82	-0.66
Net Income	0.8	0.69	0.94	0.92	0.84	0.99	0.99	0.99	0.96	0.74		0.99	0.89	0.54	0.74	0.76	0.72	0.98	0.92	0.33	0.46	0.29	0.77	-0.32
Income Before Tax	0.77	0.64	0.94	0.91	0.83	1.0	1.0	1.0	0.98	0.72	0.99		0.88	0.64	0.72	0.75	0.66	0.98	0.9	0.4	0.41	0.24	0.73	-0.28
Total Other Income Expense Net	0.69	0.59	0.81	0.79	0.73	0.86	0.86	0.86	0.89	0.63	0.89	0.88		0.45	0.64	0.63	0.73	0.88	0.99	0.26	0.37	0.15	0.68	-0.23
Income Tax Expense	0.28	0.09	0.52	0.49	0.43	0.65	0.65	0.66	0.65	0.33	0.54	0.64	0.45		0.32	0.36	0.07	0.59	0.45	0.63	-0.08	-0.18	0.23	0.15
Research Development	0.97	0.72	0.92	0.94	0.98	0.72	0.72	0.71	0.67	1.0	0.74	0.72	0.64	0.32		0.99	0.67	0.65	0.7	-0.1	0.81	0.68	0.83	-0.66
Selling General Administrative	0.96	0.66	0.93	0.95	0.98	0.74	0.74	0.74	0.68	1.0	0.76	0.75	0.63	0.36	0.99		0.7	0.68	0.7	-0.08	0.77	0.64	0.8	-0.62
Extraordinary Items	0.73	0.49	0.72	0.72	0.71	0.65	0.66	0.66	0.65	0.67	0.72	0.66	0.73	0.07	0.67	0.7		0.67	0.77	-0.21	0.53	0.37	0.7	-0.38
Net Income From Continuing Ops	0.71	0.61	0.88	0.86	0.77	0.97	0.98	0.98	0.97	0.65	0.98	0.98	0.88	0.59	0.65	0.68	0.67		0.9	0.33	0.32	0.15	0.74	-0.13
Non Operating Income Net Other	0.76	0.64	0.86	0.84	0.79	0.89	0.89	0.89	0.91	0.69	0.92	0.9	0.99	0.45	0.7	0.7	0.77	0.9		0.23	0.42	0.21	0.73	-0.28
Tax Provision	-0.01	0.08	0.19	0.16	0.02	0.41	0.4	0.4	0.4	-0.09	0.33	0.4	0.26	0.63	-0.1	-0.08	-0.21	0.33	0.23		-0.11	-0.13	0.04	0.05
Interest Income	0.85	0.72	0.66	0.7	0.74	0.41	0.41	0.39	0.32	0.81	0.46	0.41	0.37	-0.08	0.81	0.77	0.53	0.32	0.42	-0.11		0.97	0.79	-0.91
Net Interest Income	0.73	0.63	0.51	0.56	0.6	0.25	0.24	0.22	0.14	0.68	0.29	0.24	0.15	-0.18	0.68	0.64	0.37	0.15	0.21	-0.13	0.97		0.68	-0.92
Reconciled Depreciation	0.91	0.78	0.85	0.85	0.85	0.73	0.73	0.73	0.72	0.82	0.77	0.73	0.68	0.23	0.83	0.8	0.7	0.74	0.73	0.04	0.79	0.68		-0.52
Non Recurring	-0.69	-0.61	-0.51	-0.55	-0.58	-0.28	-0.27	-0.24	-0.15	-0.66	-0.32	-0.28	-0.23	0.15	-0.66	-0.62	-0.38	-0.13	-0.28	0.05	-0.91	-0.92	-0.52

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	210.3M	235.9M	286.2M	341.4M	421M	442.1M
Interest Expense	30.2M	56.9M	57.3M	59.4M	73M	76.7M
Total Revenue	7.9B	8.5B	16.1B	12.2B	13.1B	13.8B
Gross Profit	7.1B	7.4B	13.6B	10.6B	12.2B	12.8B
Other Operating Expenses	5.7B	4.9B	7.1B	7.2B	8.0B	8.4B
Operating Income	2.2B	3.6B	8.9B	4.7B	4.0B	4.2B
Ebit	2.2B	3.7B	9.0B	5.0B	4.0B	4.2B
Ebitda	2.4B	3.9B	9.3B	5.3B	4.0B	4.2B
Cost Of Revenue	782.2M	1.1B	2.4B	1.6B	883.7M	927.9M
Total Operating Expenses	4.9B	3.8B	4.7B	5.6B	7.1B	7.4B
Net Income	2.1B	3.5B	8.1B	4.3B	4.0B	4.2B
Income Before Tax	2.4B	3.8B	9.3B	4.9B	4.2B	4.4B
Total Other Income Expense Net	219.3M	233.8M	379M	119.9M	152.2M	159.8M
Income Tax Expense	313.3M	297.2M	1.3B	520.4M	245.7M	169.5M
Research Development	3.0B	2.7B	2.9B	3.6B	4.4B	4.7B
Selling General Administrative	1.8B	1.3B	1.8B	2.1B	2.6B	2.7B
Net Income Applicable To Common Shares	2.1B	3.5B	8.1B	4.3B	5.0B	5.2B
Net Income From Continuing Ops	2.1B	3.5B	8.1B	4.3B	4.0B	2.2B
Non Operating Income Net Other	249.5M	290.7M	436.3M	179.3M	206.2M	216.5M
Tax Provision	313.3M	297.2M	1.3B	520.4M	385.3M	584.1M
Interest Income	13.7M	88.1M	45.8M	160.1M	417.7M	438.6M
Net Interest Income	(30.2M)	(56.9M)	(57.3M)	100.7M	345.6M	362.9M
Reconciled Depreciation	210.3M	235.9M	286.2M	341.4M	408.1M	279.0M

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

0.86	VALN	Valneva SE ADR	Pair Corr
0.83	ERNA	Eterna Therapeutics	Pair Corr

Moving against Regeneron Stock

0.95	BMY	Bristol Myers Squibb	Pair Corr
0.85	GILD	Gilead Sciences	Pair Corr
0.74	ESPR	Esperion Therapeutics	Pair Corr
0.51	DYAI	Dyadic International	Pair Corr
0.39	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.

The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.298

Earnings Share

40.46

Revenue Per Share

128.691

Quarterly Revenue Growth

0.106

Return On Assets

0.0741

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Historical Income Statement

About Regeneron Income Statement Analysis

Regeneron Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Cost Of Revenue

Total Operating Expenses

Regeneron Pharmaceuticals income statement Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals income statement Accounts

Pair Trading with Regeneron Pharmaceuticals

Moving together with Regeneron Stock

Moving against Regeneron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit

Non Recurring	- 0.92	Net Interest Income
Non Recurring	- 0.91	Interest Income
Non Recurring	- 0.69	Depreciation And Amortization
Non Recurring	- 0.66	Research Development
Non Recurring	- 0.66	Total Operating Expenses
Non Recurring	- 0.62	Selling General Administrative